Satellos Bioscience initiates Phase 2 trial of SAT-3247 in pediatric DMD patients
Satellos Bioscience has initiated Phase 2a trial of SAT-3247 in pediatric patients with Duchenne Muscular Dystrophy (DMD), specifically targeting those aged 7 to less than 10 years.